← Back to all trials
Enrolling By Invitation
NCT06790498
Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product
Conditions: Diabetic Kidney Disease, Chronic Kidney Disease
Sex: All
Ages: 30 Years – 80 Years
Healthy volunteers: No
Enrollment: 50
Sponsor: Prokidney
Location: Boise Kidney & Hypertension Institute Meridian Idaho
Summary
The purpose of this study is to evaluate the long-term safety, efficacy, and durability in participants with chronic kidney disease (CKD) who received up to four REACT injections, delivered percutaneously into either the same or bilateral kidneys in previous studies.
Eligibility Criteria
Inclusion Criteria:
* The participant must have received REACT in a previous trial (REGEN-006, REGEN- 007, and REGEN-015) for the treatment of chronic kidney disease and completed an end of study visit in their previous trial per protocol.
* The participant is willing and able to cooperate with all aspects of the protocol.
* The participant is willing and able to provide signed informed consent.
Exclusion Criteria:
• Participant did not receive REACT in a previous trial for the treatment of chronic kidney disease
Source: ClinicalTrials.gov (NCT06790498). StuddyBuddy aggregates publicly available trial information.
